AN2 Therapeutics Reports Q2 2025: Net Loss Decreases to $6.5M, Interest Income Drops Amid Lower Cash Balances

Reuters
08/13
AN2 <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025: Net Loss Decreases to $6.5M, Interest Income Drops Amid Lower Cash Balances

AN2 Therapeutics Inc., a biopharmaceutical company specializing in novel small molecule therapeutics, has announced its financial results for the second quarter ended June 30, 2025. The company reported a net loss of $6.5 million, a significant improvement from the $14.4 million net loss reported in the same period of 2024. General and Administrative expenses increased slightly to $4.0 million from $3.7 million in the previous year, attributed to higher professional and outside services expenses. Interest income decreased to $0.8 million from $1.4 million, reflecting lower cash balances and interest rates. The company's cash, cash equivalents, and investments stood at $71.2 million as of June 30, 2025. AN2 Therapeutics projects that this cash position will fund operations into 2028. Research and Development expenses were notably reduced to $3.2 million from $12.1 million in 2024 due to a decrease in clinical trial expenses and the termination of the EBO-301 clinical study. In terms of business updates, AN2 Therapeutics made progress in its oncology programs, expecting to announce two development candidates within the next 12 months. The company also commenced dosing in a Phase 1 FIH clinical trial for Chagas Disease and continues its global health initiatives, including projects on tuberculosis and malaria, funded by a Gates Foundation grant.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250812515889) on August 12, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10